BackGiving the gift of protection to chronic kidney disease
11 March 2023
- Click on the timestamp to jump to the topic you are interested in.
- 00:01:37 Opening video00:03:46 Welcome remarks by Dr Allen Marlon Costales 0:05:46 Opening remarks by Chairperson Prof Soo Kun Lim0:11:38 Session 1: Kidney protection and why RAAS inhibitors are not enough in chronic kidney disease (CKD)? SGLT2 inhibitors: Guidelines and practice0:31:50 Checkpoint: Evidence and practice interactive session00:35:35 Session 2: Evolving role of empagliflozin in CKD beyond glucose control 01:15:41 Case discussion: T2D patient with low albuminuria diagnosed with CKD
- Q&A:
- 01:26:50 Given the SGLT2 inhibitor data, what would be your first line treatment for a diabetic kidney disease patient without proteinuria?01:33:36 What is the rationale and evidence for reducing LDL <1.4 in the CKD population?01:36:24 If there is a patient with a low risk of progression and do not have albuminuria, will you use a RAS blocker with an SGLT2 inhibitor? 01:38:47 In a patient with IGA nephropathy, with CKD and no albuminuria, do we have to change our practice from using only a RAS blocker to treat hypertension, to adding in an SGLT2 inhibitor? 01:40:49 Would you use an SGLT2 inhibitor in type one diabetes? 01:43:11 What dose would we choose when we use SGLT2 inhibitors in patients with CKD, 10 or 25 mg? 01:44:35 If eGFR dropped to less than 90 because of aging, is there any value of using SGLT2 inhibitors? 01:47:50 Is empagliflozin more superior in providing renal protection in patient with CKF compared to insulin? 01:54:49 Is there any additional benefit/evidence in retarding CKD progression or HF incidence with a higher dose of empagliflozin (25 mg)? 01:55:27 Nowadays when you start on SGLT2 inhibitors, do you still make a point to ask a patient to come back 2 or 4 weeks later to check their kidney function? 01:57:21 In your opinion, is there a class effect with the SGLT2 inhibitors or should they be differentiated based on the trial data? 02:01:40 Key takeaways and closing
×
Prof Per Henrik Groop
University of Helsinki, Finland
- Professor of Internal Medicine (Chair) at the University of Helsinki
- Graduated from Medicine the University of Helsinki and postdoctoral studies at the Guy’s Hospital, University of London
- Chief Physician at the Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital
- Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland
- Professor at the Department of Diabetes, Central Clinical School at the Monash University in Melbourne, Australia
- Research is focused on the dissection of the pathogenesis of diabetic complications with special emphasis on diabetic nephropathy
×
Prof Soo Kun Lim
University of Malaya Medical Center Malaysia
- Associate Professor & Senior Consultant Nephrologist Head, Renal Division, Department of Medicine, University Malaya Medical Center
- Bachelor of Medicine and Bachelor of Surgery, MBBS, University of Malaya
- Member of Royal College of Physicians, MRCP
- Fellow Royal College of Physicians (Edinburg), FRCP (Edin)
- Member of the Malaysia Society of Nephrology (MSN) and Malaysia Society of Transplantation (MST)
- Dialysis Committee & Technical Committee Chair and Board Member of the National Kidney Foundation
